Antibody Market Partnering Terms and Agreements 2010 to 2016

PUNE, India, August 15, 2016 /PRNewswire/ --

ReportsnReports.com adds "Global Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials" market research report providing comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the world's leading healthcare companies.  The report provides a detailed understanding and analysis of how and why companies enter Antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering: Antibodies, Antibody-drug conjugates, Monoclonal antibodies, Murine mAb, Chimeric mAb, Humanized mAb, Human aAb and Polyclonal Antibodies. Complete report on Global Antibody Market Partnering Terms and Agreements with 7 Chapters and 13 figures, spread across 829 pages is available at http://www.reportsnreports.com/reports/152018-global-antibody-partnering-terms-and-agreements-2010-2016-deal-trends-players-and-financials.html .

This report contains over 1,200 links to online copies of actual Antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of Antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Antibody dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms

Chapter 3 provides a review of the leading Antibody deals since 2010. Deals are listed by headline value, signed by big pharma, most active Antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in Antibody dealmaking with a brief summary followed by a comprehensive listing of Antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Order a copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=152018 .

Chapter 5 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan to 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Chapter 6 provides Antibody dealmaking by technology type.

Chapter 7 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan to 2010. The chapter is organized by specific Antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Antibody Partnering Terms and Agreements includes: In-depth understanding of Antibody deal trends since 2010; Access to headline, upfront, milestone and royalty data; Analysis of the structure of Antibody agreements with real life case studies; Detailed access to actual Antibody contracts enter into by the leading fifty bigpharma companies; Insight into the terms included in a Antibody agreement, together with real world clause examples; Understand the key deal terms companies have agreed in previous deals; Undertake due diligence to assess suitability of your proposed deal terms for partner companies.

Another newly published market research report titled on Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the world's leading healthcare companies. This report contains a comprehensive listing of all Cancer monoclonal antibody partnering deals announced since Jan 2010, including financial terms where available, including links to online deal records of actual Cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. The report also includes numerous tables and figures that illustrate the trends and activities in Cancer monoclonal antibody partnering and dealmaking since 2010. Cancer Monoclonal Antibody Partnering Terms and Agreements research report of 1000 pages is available at http://www.reportsnreports.com/reports/155956-global-cancer-monoclonal-antibody-partnering-terms-and-agreements-2010-2016-deal-trends-players-and-financials.html .

Explore more reports on Biotechnology.

About Us: 

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com

Connect With Us on:
Facebook:  https://www.facebook.com/ReportsnReports/
LinkedIn:  https://www.linkedin.com/company/reportsnreports
Twitter:  https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
RSS/Feeds:  http: //http://www.reportsnreports.com/feed/l-latestreports.xml

SOURCE ReportsnReports